RC
ABUS icon

Rangeley Capital’s Arbutus Biopharma ABUS Stock Holding History

Rangeley Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.25M Sell
500,000
-340,000
-40% -$1.49M 2.19% 9
2025
Q4 		$4.04M Hold
840,000
– – 3.36% 7
2025
Q3 		$3.81M Sell
840,000
-25,000
-3% -$91.8K 3.3% 9
2025
Q2 		$2.67M Sell
865,000
-484,000
-36% -$1.61M 3.19% 13
2025
Q1 		$4.71M Sell
1,349,000
-110,000
-8% -$367K 5.04% 3
2024
Q4 		$4.77M Buy
+1,459,000
New +$5.37M 4.28% 6

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Rangeley Capital's ABUS Position: Q1 2026 in Review

Rangeley Capital reduced its Arbutus Biopharma (ABUS) stake by 40% in Q1 2026, selling an estimated $1.49M and leaving 500,000 shares worth $2.25M. The position accounts for 2.19% of the portfolio, ranked #9.

Rangeley Capital first reported a position in ABUS in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.77M in Q4 2024. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Rangeley Capital held 500,000 shares of Arbutus Biopharma worth $2.25M as of Q1 2026.
  • Rangeley Capital sold 340,000 Arbutus Biopharma shares in Q1 2026, an estimated $1.49M.
  • Arbutus Biopharma made up 2.19% of Rangeley Capital's portfolio in Q1 2026, its #9 holding.
  • Rangeley Capital first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 6 quarters since.
  • Rangeley Capital's Arbutus Biopharma position peaked at $4.77M in Q4 2024.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.